KA
Therapeutic Areas
Lanier Biotherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Checkpoint Inhibitor Pneumonitis (CIP) Program | Checkpoint Inhibitor Pneumonitis | Pre-clinical |
| Type 2 Inflammation / Fibrosis Program | Asthma, Atopic Dermatitis, Chronic Rhinosinusitis with Nasal Polyps, Eosinophilic Esophagitis, Food Allergies | Pre-clinical |
| Retinal Program | Retinal diseases (e.g., Age-related Macular Degeneration) | Pre-clinical |
Leadership Team at Lanier Biotherapeutics
DW
Daniel White
Chief Executive Officer & Director
MS
Martin Simonetti
Director
CM
Christopher McLeod
Director